What is Alamar Biosciences 's additional paid-in capital?

Alamar Biosciences (ALMR) reported additional paid-in capital of $12.11M in Q1 2026.

What does additional paid-in capital mean?

Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.

Alamar Biosciences ALMR Additional Paid-In Capital

Additional Paid-In Capital at other companies

Williams-SonomaWSM

$517.77M-1.3%

UL SolutionsULS

$888M+7.1%

3MMMM

$7.5B+2.7%

Devon EnergyDVN

$5.32B-12.8%

Fidelity National FinancialFNF

$6.07B+1.0%

KrogerKR

$3.91B+26.6%

Other financials

Income statement

See full

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

See full

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

See full

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

See full

Market cap$1.52B—

Enterprise value$1.49B—

Returns & leverage

See full

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alamar Biosciences 's additional paid-in capital?: Alamar Biosciences (ALMR) reported additional paid-in capital of $12.11M in Q1 2026.
What does additional paid-in capital mean?: Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.